This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kahl-McDonagh, M. M. Articles by Ficht, T. A. Search for Related Content PubMed PubMed Citation Articles by Kahl-McDonagh, M. M. Articles by Ficht, T. A.

 Previous Article  |  Next Article 

Infection and Immunity, July 2006, p. 4048-4057, Vol. 74, No. 7
0019-9567/06/$08.00+0     doi:10.1128/IAI.01787-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Evaluation of Protection Afforded by Brucella abortus and Brucella melitensis Unmarked Deletion Mutants Exhibiting Different Rates of Clearance in BALB/c Mice

Department of Pathobiology, College of Veterinary Medicine, Texas A&M University, College Station, Texas 77843-4467

Received 3 November 2005/ Returned for modification 27 January 2006/ Accepted 14 April 2006

Research for novel Brucella vaccines has focused upon the development of live vaccine strains, which have proven more efficacious than killed or subunit vaccines. In an effort to develop improved vaccines, signature-tagged mutant banks were screened to identify mutants attenuated for survival. Mutants selected from these screens exhibited various degrees of attenuation characterized by the rate of clearance, ranging from a failure to grow in macrophages after 24 h of infection to a failure to persist in the mouse model beyond 8 weeks. Ideal vaccine candidates should be safe to the host, while evoking protective immunity. In the present work, we constructed unmarked deletion mutants of three gene candidates, manBA, virB2, and asp24, in both Brucella abortus and Brucella melitensis. The asp24 mutants, which persist for extended periods in vivo, are superior to current vaccine strains and to other deletion strains tested in the mouse model against homologous challenge infection after 12, 16, and 20 weeks postvaccination. The asp24 mutants also display superior protection compared to manBA and virB2 mutants against heterologous challenge in mice. From this study, a direct association between protection against infection and cytokine response was not apparent between all vaccine groups and, therefore, correlates of protective immunity will need to be considered further. A distinct correlation between persistence of the vaccine strain and protection against infection was corroborated.

Editor: V. J. DiRita

This article has been cited by other articles:

• Rolan, H. G., Tsolis, R. M. (2008). Inactivation of the Type IV Secretion System Reduces the Th1 Polarization of the Immune Response to Brucella abortus Infection. Infect. Immun. 76: 3207-3213 [Abstract] [Full Text]  
• Arenas-Gamboa, A. M., Ficht, T. A., Kahl-McDonagh, M. M., Rice-Ficht, A. C. (2008). Immunization with a Single Dose of a Microencapsulated Brucella melitensis Mutant Enhances Protection against Wild-Type Challenge. Infect. Immun. 76: 2448-2455 [Abstract] [Full Text]  
• Rolan, H. G., den Hartigh, A. B., Kahl-McDonagh, M., Ficht, T., Adams, L. G., Tsolis, R. M. (2008). VirB12 Is a Serological Marker of Brucella Infection in Experimental and Natural Hosts. CVI 15: 208-214 [Abstract] [Full Text]  
• Pei, J., Wu, Q., Kahl-McDonagh, M., Ficht, T. A. (2008). Cytotoxicity in Macrophages Infected with Rough Brucella Mutants Is Type IV Secretion System Dependent. Infect. Immun. 76: 30-37 [Abstract] [Full Text]  
• Kahl-McDonagh, M. M., Arenas-Gamboa, A. M., Ficht, T. A. (2007). Aerosol Infection of BALB/c Mice with Brucella melitensis and Brucella abortus and Protective Efficacy against Aerosol Challenge. Infect. Immun. 75: 4923-4932 [Abstract] [Full Text]